RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme encoded by the RAF1 gene. The RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline drugs market research report provides comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
RAF1 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas of the RAF1 pipeline drugs market are oncology and genetic disorders. Oncology dominates the pipeline market.
RAF1 Pipeline Drugs Market Analysis, by Therapy Areas
For more RAF1 pipeline drugs market therapy areas insights, download a free report sample
RAF1 Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanism of action of the RAF1 pipeline drugs market is RAF Proto Oncogene Serine/Threonine Protein Kinase Inhibitor.
RAF1 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the RAF1 pipeline drugs market are oral, intravenous, ophthalmic, and intratumor. Most of the pipeline products are administered by the oral route.
RAF1 Pipeline Drugs Market Analysis, by Routes of Administration
For more RAF1 pipeline drugs market routes of administration insights, download a free report sample
RAF1 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the RAF1 pipeline drugs market are small molecule, antisense RNAi oligonucleotide, peptide, and synthetic peptide. Small molecule dominates the pipeline drugs market.
RAF1 Pipeline Drugs Market Analysis, by Molecule Types
To know more about the molecule types in the RAF1 pipeline drugs market, download a free report sample
RAF1 Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the RAF1 pipeline drugs market are Apollomics Inc, Bayer AG, Chengdu Fanxi Biopharma Co Ltd, Deciphera Pharmaceuticals Inc, Hanmi Pharmaceuticals Co Ltd, Jazz Pharmaceuticals Plc, Metagone Biotech Inc, Novartis AG, Quanta Therapeutics Inc, and Samjin Pharm Co Ltd.
RAF1 Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the RAF1 pipeline drugs market, download a free report sample
RAF1 Pipeline Drugs Market Report Overview
| Key Therapy Areas | Oncology and Genetic Disorders |
| Key Mechanism of Action | RAF Proto Oncogene Serine/Threonine Protein Kinase Inhibitor |
| Key Routes of Administration | Oral, Intravenous, Ophthalmic, and Intratumor |
| Key Molecule Types | Small Molecule, Antisense RNAi Oligonucleotide, Peptide, and Synthetic Peptide |
| Leading Companies | Apollomics Inc, Bayer AG, Chengdu Fanxi Biopharma Co Ltd, Deciphera Pharmaceuticals Inc, Hanmi Pharmaceuticals Co Ltd, Jazz Pharmaceuticals Plc, Metagone Biotech Inc, Novartis AG, Quanta Therapeutics Inc, and Samjin Pharm Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1).
- Reviews of RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects.
- Assessment of RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on MoA, RoA, and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Bayer AG
Chengdu Fanxi Biopharma Co Ltd
Deciphera Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Novartis AG
Quanta Therapeutics Inc
Samjin Pharm Co Ltd
Sirnaomics Ltd
SyntheX Inc
Takeda Pharmaceutical Co Ltd
Verastem Inc
Table of Contents
Frequently asked questions
-
What are the key therapy areas of the RAF1 pipeline drugs market?
The key therapy areas of the RAF1 pipeline drugs market are oncology and genetic disorders.
-
What are the key mechanisms of action of the RAF1 pipeline drugs market?
The key mechanism of action of the RAF1 pipeline drugs market is RAF Proto Oncogene Serine/Threonine Protein Kinase Inhibitor.
-
What are the key routes of administration in the RAF1 pipeline drugs market?
The key routes of administration in the RAF1 pipeline drugs market are oral, intravenous, ophthalmic, and intratumor.
-
What are the key molecule types in the RAF1 pipeline drugs market?
The key molecule types in the RAF1 pipeline drugs market are small molecule, antisense RNAi oligonucleotide, peptide, and synthetic peptide.
-
Which are the leading companies in the RAF1 pipeline drugs market?
Some of the leading companies in the RAF1 pipeline drugs market are Apollomics Inc, Bayer AG, Chengdu Fanxi Biopharma Co Ltd, Deciphera Pharmaceuticals Inc, Hanmi Pharmaceuticals Co Ltd, Jazz Pharmaceuticals Plc, Metagone Biotech Inc, Novartis AG, Quanta Therapeutics Inc, and Samjin Pharm Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports